In stock
Trazimera 440 mg Powder for concentrate for solution for infusion Vial
In stock
Only 1 left
SKU
10331014278
Trazimera 440 mg is a targeted therapy containing trastuzumab, a biosimilar monoclonal antibody, used to treat HER2-positive breast cancer and HER2-positive metastatic gastric cancer. It works by specifically targeting the HER2 protein to inhibit tumor cell growth. This prescription medication is administered via intravenous infusion under medical supervision.
Product Overview
Discover comprehensive details about Trazimera 440 mg on leading pharmaceutical and e-commerce platforms such as Nahdi Online, , and , where you can often find product information and availability.
Trazimera 440 mg Powder for concentrate for solution for infusion is a targeted therapy indicated for the treatment of certain types of cancer.
This medication contains trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, which specifically targets the human epidermal growth factor receptor 2 (HER2) protein.
HER2 is a protein that can be found in high amounts on the surface of some cancer cells and plays a crucial role in cancer cell growth and survival.
Trazimera is a biosimilar to Herceptin (trastuzumab), offering an effective treatment option.
Benefits of Use
Trazimera is highly effective in the treatment of HER2-positive breast cancer and HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.
It works by binding to the HER2 receptor, thereby inhibiting the growth and proliferation of HER2-overexpressing tumor cells.
When used alone or in combination with chemotherapy, Trazimera has been shown to improve progression-free survival and overall survival in eligible patients.
It represents a vital component in modern oncology treatment regimens for HER2-positive malignancies.
How to Use
Trazimera 440 mg Powder for concentrate for solution for infusion must be prepared and administered by a healthcare professional.
It is given as an intravenous (IV) infusion.
The specific dosage and duration of treatment will be determined by your doctor based on your medical condition, body weight, and response to therapy.
The infusion process typically involves:
1. Reconstitution of the powder for concentrate with sterile water for injection.
2. Further dilution of the reconstituted solution with sodium chloride 0.9% injection.
3. Slow intravenous infusion, typically over 30 to 90 minutes, depending on the dose and patient tolerance.
4. Close monitoring by medical staff during and after the infusion for any potential reactions.
Caution & Warnings
- Infusion-related reactions: Patients may experience fever, chills, nausea, vomiting, pain, headache, dizziness, rash, or shortness of breath during or shortly after infusion. Severe reactions are rare but require immediate medical attention.
- Cardiotoxicity: Trazimera can cause heart problems, including congestive heart failure. Patients should have cardiac function assessed before and during treatment.
- Pulmonary toxicity: Serious lung adverse reactions have been reported, including dyspnea, pleural effusion, and interstitial pneumonitis.
- Embryo-fetal toxicity: Trazimera can cause fetal harm when administered to a pregnant woman. Effective contraception should be used during treatment and for 7 months after the last dose.
- Patients with known hypersensitivity to trastuzumab or any excipients should not use this product.
- This product must only be administered under the supervision of a physician experienced in the administration of antineoplastic agents.
Ingredients
Active Ingredient: Trastuzumab 440 mg
Excipients: Sucrose, Polysorbate 20, L-Histidine, L-Histidine hydrochloride monohydrate (exact composition may vary slightly by formulation and region, refer to the specific product leaflet).
Product Details
Manufacturer: Pfizer
Product Type: Biosimilar Monoclonal Antibody
Form: Powder for concentrate for solution for infusion
Strength: 440 mg per vial
Therapeutic Area: Oncology
| Gtin | 1306210785 |
|---|---|
| Recommended Sale Price | 3019.6 |
| Is Wasfaty Product | No |
| Brand | Not Defined |
| Ingredient Name | Trastuzumab |
| SFDA Reg. No | 1306210785 |
| IBC | 1306210785 |
| Drug Type | prescription |
| Scientific Name | Trastuzumab |
| Strength | 440 |
| Strength Unit | mg |
| Form | Powder for concentrate for solution for infusion |
| Admin Route | intravenous |
| Size | 440 |
| Size Unit | mg |
| Package Types | Vial |
| Package Size | 1 vial |
| shelfLife | 48 months |
| Storage conditions | Store unopened vial in a refrigerator (2 degrees Celsius to 8 degrees Celsius). Do not freeze. Keep the vial in the outer carton to protect from light. |
| Refrigerator Storage | Yes |
Products you might like
